Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 714-722

  Dawson, Mark A ^a   Opat, Stephen S ^a   Taouk, Yamna ^a   Donovan, Mark ^a   Zammit, Michele ^a   Monaghan, Katherine ^a   Horvath, Noemi ^b   Roberts, Andrew W ^a   Prince, H Miles ^a   Hertzberg, Mark ^c   McLean, Catriona A ^a   Spencer, Andrew ^a,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL CYCLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL CYCLE; COHORT STUDIES; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 59449104370     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1022     Document Type: Article

References (43)

1. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
2. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132:410-51.
3. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in mul-tiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91 -7.
5. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
6. Adams J. The proteasome: structure, function, and role in the cell. CancerTreat Rev 2003;29 Suppl 1:3-9.
7. Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 2006;3:374-87.
8. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
9. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
10. Mitsiades N, Mitsiades CS, PoulakiV, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.
11. HideshimaT, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of protea some inhibitor PS-341. Blood 2003:101:1530-4.
12. Jagannath S, Richardson PG, Sonneveld P, et al Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151 -7.
13. Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma Blood 2005;106:2977-81.
14. Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates anc duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21:164-8.
15. Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 2006;47:2289-300.
16. Chang H, Stewart AK, Qi XY, Li ZH, Yi QL,Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005;106:353-5.
17. Mikhael JB, Belch A, Prince HM, et al. Preliminary safety and efficacy results from an international phase 3b study for expanded access to bortezomib in 624 patients with relapsed and/or refractory multiple myeloma. Blood 2006;108:3530a.
18. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901.
19. Niesvizky R, Richardson PG, Rajkumar SV, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 2008;143:46-53.
20. Uchida T, Kinoshita T, OhnoT, Ohashi H, Nagai H, Saito H. Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia 2001;15:157-65.
21. Chng WJ, Price-TroskaT, Gonzalez-Paz N, et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007;21:582-4.
22. Gonzalez-Paz N, Chng WJ, McClure RF, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007;109:1228-32.
23. Ohtani N, Yamakoshi K, Takahashi A, Hara E. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest 2004;51:146-53.
24. Dib A, Barlogie B, Shaughnessy JD, Jr., Kuehl WM Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 2007;109:1337-8.
25. + anaplastic large cell lymphoma. Leukemia 2007;21:838-42.
26. Coquelle A, Mouhamad S, Pequignot MO, et al. Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells. Cell Death Differ 2006;13:873-5.
27. Barille-Nion S, Barlogie B, Bataille R, et al. Advances in biology and therapy of multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2003;248-78.
28. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002;99:1885-93.
29. Fonseca R, Witzig TE, Gertz MA, et al. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol 1998;101:296-301.
30. Hoechtlen-VollmarW, Menzel G, Bartl R, Lamerz R, Wick M, Seidel D. Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol 2000;109:30-8.
31. Konigsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000;18:804-12.
32. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-6.
33. Soverini S, Cavo M, Cellini C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003;102:1588-94.
34. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001;97:822-5.
35. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100:1579-83.
36. Ishii Y, Pirkmaier A, Alvarez JV, et al. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 2006;98:1238-47.
37. Quintanilla-Martinez L, Kremer M, Specht K, et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 2003;162:1449-61.
38. Fisher Rl, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-74.
39. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-88.
40. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32.
41. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165-72.
42. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-ltalian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-65.
43. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007;12:235-9.